超碰碰97,日韩人妻一区二区三区蜜桃视频,日韩综合人妻Av,天天日天天干天天爽天天日天天做

加入收藏 | 設為首頁 | 聯(lián)系我們

產品搜索

聯(lián)系我們

聯(lián)系人:蔣經理
電話:4008750250
號碼:
手機:18066071954
地址:南京市棲霞區(qū)緯地路9號
Email: zhangxiangwen@cobioer.com

產品展示 / PRODUCTS
藥靶細胞株 > kinase激酶細胞株 > CBP73190BCR-ABL1 T315I/BaF3

BCR-ABL1 T315I/BaF3
名稱 BCR-ABL1 T315I/BaF3
型號 CBP73190
報價
特點 BCR-ABL1 [T315I]/BaF3,母細胞:BaF3,凍存條件:90% FBS+10% DMSO;
  • 詳細內容
CBP73190
I. Introduction

Cell Line Name:

BCR-ABL1 [T315I]/BaF3

Host Cell:

Ba/F3

Stability:16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.)

Application:

Anti-proliferation assay and PD assay

Freeze Medium:

90% FBS+10% DMSO

Complete Culture Medium:

RPMI-1640+10%FBS

Mycoplasma Status:

Negative

 
II.Background

Presence of a BCR-ABL1 fusion gene is necessary for the pathogenesis of CML. In up to 95% of cases, a t(9;22) (q34;q11) translocation results in the BCR-ABL1 fusion gene (Faderl et al. 1999). This translocation results in the Philadephia chromosome. In rare CML cases lacking the traditional t(9;22) translocation, other translocations result in the creation of the BCR-ABL1 fusion gene, which sometimes involve multiple chromosomes.
ABL1 is a tyrosine kinase, and, in normal cells, it plays a role in cellular differentiation and regulation of the cell cycle. The BCR-ABL1 fusion gene creates a constitutively active tyrosine kinase, which leads to uncontrolled proliferation.
Imatinib is the first-generation ABL tyrosine kinase inhibitor, and it was approved by the FDA in 2001; label indications for CML include use in newly diagnosed adult and pediatric patients and in patients after failure of interferon-alpha therapy. While treatment responses to imatinib are often dramatic and lasting, 30–40% of patients will eventually need further treatment (Santos et al. 2011). In many but not all cases, this is due to the acquisition of point mutations in the tyrosine kinase domain of the BCR-ABL1 fusion gene, which renders the protein insensitive to the inhibitory effect of imatinib. This type of disease progression led to the development of second-line TKIs: dasatinib, nilotinib, and bosutinib. Dasatinib and bosutinib have the additional advantage of being inhibitors of SRC.
The second-generation TKIs, dasatinib, nilotinib, and bosutinib, are more potent than imatinib, and they were developed to treat cases of CML resistant to imatinib. Dasatinib and nilotinib are approved for use in CML in newly diagnosed adults, while dasatinib, nilotinib, and bosutinib are approved for use in adults with resistance or intolerance to prior therapy that included imatinib (FDA 2012). Soverini et al. (2011) made mutation-specific treatment decision recommendations that were adopted by NCCN (2012). Recommendations based on preclinical data are as follows: for T315I, HSCT or clinical trial; for V299L, T315A, and F317L/V/I/C, consider nilotinib rather than dasatinib; for Y253H, E255K/V, and F359V/C/I, consider dasatinib rather than nilotinib; and for all other mutations, consider high-dose imatinib, dasatinib, or nilotinib.
Ponatinib is a third-line TKI, developed specifically to address imatinib resistance due to the BCR-ABL1 T315I resistance mutation. Ponatinib is currently being investigated in phase III clinical trials.

 
III. Representative Data

1. WB of BCR-ABL1 [T315I]/BaF3


2. Sanger of BCR-ABL1 [T315I]/BaF3


Figure 2. BCR-ABL1 T315I/BaF3 T315I

Figure 3. BCR-ABL1 T315I/BaF3 Fusion

 

3. Anti-proliferation assay

Figure 4. CTG Proliferation Assay of BaF3 BCR-ABL1 T315I Cells.

如果你對CBP73190BCR-ABL1 T315I/BaF3感興趣,想了解更詳細的產品信息,填寫下表直接與廠家聯(lián)系:


留言框

  • 產品:

  • 您的單位:

  • 您的姓名:

  • 聯(lián)系電話:

  • 常用郵箱:

  • 省份:

  • 詳細地址:

  • 補充說明:

  • 驗證碼:

    請輸入計算結果(填寫阿拉伯數字),如:三加四=7

化工儀器網

推薦收藏該企業(yè)網站
五十路午夜福利| 婷五月天中文字幕婷| 欧美lily黑手1区2区免费在线| 人人人人人,爽影院| 日韩天天干在线| 岛国亚洲女三干一| 国产人妻爽到欲仙欲死| 日韩性生活视频群交| 射射国产的视频| 午夜人妻影音| 激情国产日韩欧美| 成年人又黄又爽又色| 亚洲一区二禽兽呦呦| 一区二区三区在线蜜桃| 久久日一区二区| 亚洲欧洲另类| 久久少妇AV一区| 亚洲免费诱惑视频| 欧美黄片第二页| 国产精品99999中文| AV中文字幂一区| 欧美h| 一区二区三区精品化| 亚洲欧美日韩精品久久精品久久| 欧美一级二级在线| 亚洲熟妇无码精品久久疯| 欧美大牌不卡一区| 97精品一区二区三区麻豆| 亚洲人成久久网| 伊人日本专区| 欧美性爱美女自慰网站上二区| 亚洲伦理亚洲| 亚洲黄色录像AV| 亚洲激情1区2区3区| 改则县| 热99精品这里有| 久久久久电影中出| 亚洲123区无码在线观看| 乳交中文字幕三区| 久久久久久无码高清| 无码中文字幕三区|